Profile

Paul A. Carpenter, MD

On staff since June 1999

Academic Title: Associate Professor

"One of the most rewarding aspects of my work is the privilege of forging long-term relationships with families who are faced with what must be one of the most challenging experiences of their lives – caring for a child with a life-threatening disorder that is potentially treatable by stem cell transplantation. When I see patients, I try to listen attentively and maintain open communication. I focus on empowering patients and their families with evidence-based knowledge and offering them treatment options that focus on quality of life."

Paul Carpenter, MBBS, is attending physician at Seattle Children’s Hospital and Fred Hutchinson Cancer Research Center (FHCRC) and associate professor at the University of Washington, with a focus on graft versus host disease (GVHD). He supervises junior attending staff on the pediatric hematopoietic cell transplant service at FHCRC. His local responsibilities include long-standing contributions to the FHCRC Standard Practice Committee and Standard Practice Manual.

He chairs a Data Safety Monitoring Board for multiple FHCRC protocols and serves on the FHCRC Scientific Review Committee and one of the two Institutional Review Boards. His clinical and research interests focus on GVHD, which is the major and potentially lethal complication of hematopoietic cell transplant. His research continues to explore new therapies for the treatment of acute and chronic GVHD, and he is an active member in the national efforts to advance the field of chronic GVHD treatment. He is studies therapies designed to ameliorate key morbidities associated with chronic immunosuppressive therapies, such as bisphosphonate therapy for glucocorticoid-induced bone disease and the use of statins to treat hyperlipidemia. He has designed and participated in studies to evaluate the safety and efficacy of tyrosine kinase inhibitors as post-transplant therapy for high-risk Philadelphia chromosome–positive leukemias and for the treatment of chronic graft versus host disease. He is currently a Principal Investigator of the inaugural Blood and Marrow Clinical Trials Network (BMT CTN) Phase II/III 0801 trial for chronic graft-versus-host-disease.

Recommendations

Recommend Dr. Paul Carpenter

Overview
Awards and Honors
Publications
Presentations
Research Funding

Overview

Board Certification(s): General Pediatrics (Non-ABMS)
Medical/Professional School: University of Sydney, Sydney, New South Wales
Residency: Pediatrics, Sydney Children's Hospital, Sydney
Fellowship: Pediatric Oncology, Sydney Children's Hospital, Sydney
Pediatric Hematology-Oncology, University of Washington School of Medicine, Seattle
Clinical Interests: Graft vs. host disease, Long-term follow-up after hematopoetic cell transplantation

Awards and Honors

Award Name	Award Description	Awarded By	Award Date
U.S. News Top Doctor		U.S. News and World Report	2012
Seattle Magazine Top Doctor - 2012	Seattle Magazine Top Doctor - 2012	Seattle Magazine	2012

Publications

Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2010 Sep: 1237-44

Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2010 Aug 30

Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.
The Journal of allergy and clinical immunology , 2010 Jul 17

Comparison between short-term response and long-Term outcomes after initial systemic treatment of chronic graft-Versus-Host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2010 Jul 2

Management of acute graft-versus-host disease in children.
Pediatric clinics of North America , 2010 Feb: 273-95

Successful unrelated donor cord blood transplantation for Glanzmann's thrombasthenia.
Pediatric transplantation , 2009 Oct 22

Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.
Blood , 2009 Jul 16: 702-8

Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2009 Jun: 749-56

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
Blood , 2009 May 21: 5074-82

Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2009 Apr: 416-20

Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.
Blood , 2009 Mar 26: 2888-94

Thyroid function following hematopoietic cell transplantation in children: 30 years' experience.
Blood , 2009 Jan 8: 306-8

Late effects of chronic graft-versus-host disease.
Best practice & research. Clinical haematology , 2008 Jun: 309-31

Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2008 May: 531-7

Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2007 Sep: 1016-21

Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2007 Jun: 683-90

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
Blood , 2007 Apr 1: 2791-3

Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2006 Jul: 792-4

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2005 Jun: 465-71

Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.
Blood , 2005 May 1: 3749-56

Final adult height of patients who received hematopoietic cell transplantation in childhood.
Blood , 2005 Feb 1: 1348-54

Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Blood , 2004 Dec 1: 3501-6

Diagnosis and clinical management of chronic graft-versus-host disease.
International journal of hematology , 2004 Apr: 221-8

Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2003 Nov: 706-13

Steroid-refractory graft-vs.-host disease: past, present and future.
Pediatric transplantation , 2003: 19-31

Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale.
Blood , 2002 Jun 1: 4245-6

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
Blood , 2002 Apr 15: 2712-9

Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2002: 206-12

Presentations

Presentations Title	Event	Location	Date
Lectures 1-3	XIII Congress of the Brazilian Society of BMT	Curitiba	Aug. 3, 2009
Endpoints for Clinical Trials in Acute GVHD	FDA	Bethesda, MD	May 19, 2009
EBMT	Göteborg	Sweden	March 29, 2009

Research Funding

Grant Title	Grantor	Award Date
Unknown	BMT CTN Protocol 0801	Jan. 1, 2009
Unknown	Osiris Therapeutics, Inc	Jan. 1, 2008
Unknown	Novartis Pharmaceuticals Corp	Jan. 1, 2008

Primary Office

Fred Hutchinson Cancer Research Center

FHCRC Box 358080 - MS D5-290
PO Box 19024

Seattle, WA 98109-1024

206-667-3786

Additional Offices

Seattle Children's

MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE

Seattle, WA 98105

206-987-2106

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

First

Last

Specialty:

Location: Language (Other than English): Research Area of Focus: Research Center:

More search options

Paul A. Carpenter, MD

Recommendations

Overview

Awards and Honors

Publications

Presentations

Research Funding

Primary Office

Additional Offices

Find a Doctor or Researcher

Sections

Information For

About Us

What’s New

About This Site